FDA Panel Votes on BPC-157 and 6 Peptides: What Changed, What Didn't and What's Next

An FDA advisory committee voted in July 2026 to recommend that six peptides, including BPC-157 and TB-500, be added to the list of substances pharmacies may use for compounding. That vote did not approve any peptide, did not change the law, and went against the recommendation of FDA's own scientists. As of 11 October 2026, FDA has not published a decision or a proposed rule, so none of the seven peptides reviewed has been added to the list.¹²³

This article explains what was decided, what was not, why FDA's reviewers said no, and what to watch next. It also covers two related developments: athletes face a clearer anti-doping rule for peptides from 2027, and FDA continues to warn sellers who market injectable peptides as "research chemicals". It describes the regulatory process only. It is not legal or medical advice and gives no dosing information.

The short version

• What happened: On 23–24 July 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides nominated for the 503A Bulks List. It voted to recommend six of them: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It voted against emideltide (DSIP).¹⁴⁵
• What FDA's scientists said: In its briefing documents, FDA proposed that none of the seven be added. For BPC-157 it found the substance "not well-characterized" and a "lack of evidence" for effectiveness in the condition reviewed.²³
• What it does not mean: An advisory vote is a recommendation. It is not FDA approval, and it does not let pharmacies compound these peptides. FDA would first have to agree and then complete notice-and-comment rulemaking.²⁵
• For athletes: From 1 January 2027, WADA's Prohibited List names "peptides" in general under S0, its class for non-approved substances, which are banned at all times.⁸
• For buyers: FDA's August 2026 warning letter to a "research peptide" seller says a "research use only" label does not protect a product that is marketed for human use.⁹

What is the 503A Bulks List, and why does it matter?

Most drugs reach patients through FDA approval: a manufacturer proves to FDA that a specific product is safe and effective, and is made to set quality standards. Compounding is different. A licensed pharmacist or physician prepares a medication for an individual patient, and compounded products are not FDA-approved. Read our guide to compounded peptides and what FDA approval means.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound with a bulk drug substance only if it meets one of three conditions²:

1. It complies with a United States Pharmacopeia (USP) or National Formulary monograph, if one exists.
2. It is a component of an FDA-approved drug.
3. It appears on the 503A Bulks List, which FDA creates through formal regulations.

Peptides such as BPC-157, TB-500 and MOTS-c have no USP monograph and are not ingredients of any approved medicine. The 503A Bulks List is therefore the only federal route that would allow pharmacies to compound them. That is why this vote drew so much attention.

FDA judges nominated substances against four criteria and weighs them together, substance by substance: physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding.²

How the committee voted

The committee met at FDA's White Oak campus in Silver Spring, Maryland. FDA's meeting page lists the substances and the specific uses that were reviewed.¹ FDA had not posted official vote results or minutes on that page at the time of writing, so the tallies below come from contemporaneous news reports. They agree with each other.⁴⁵⁶

Each recommendation applies to the use reviewed. For example, the BPC-157 discussion concerned ulcerative colitis, not tendon repair, gut health in general or "recovery".

AJMC reported that FDA scientists had recommended against all seven substances and that the committee's votes went against that written advice, which observers described as highly unusual.⁵ Members were divided. RAPS Regulatory Focus quoted one member who voted yes "because it's time to put this decision back in the hands of the physician and pharmacist", and another who said, "There are too many unknowns about this product."⁷ The committee had recently been reconstituted with more members who prescribe or use peptides in practice, which drew conflict-of-interest scrutiny.⁵

Why FDA's own reviewers said no

FDA's briefing documents are public, and they are the clearest guide to the agency's thinking. For BPC-157, FDA concluded that "a balancing of the criteria weighs against" adding it, for three main reasons³:

• Quality and identity. FDA called BPC-157 "not well-characterized". It cited inconsistent naming and missing or inadequate data on identity, purity, peptide-related impurities and aggregates, microbial quality and other quality attributes. At the meeting, an FDA official said, "We cannot establish quality standards".³⁷
• Effectiveness. After reviewing the literature, FDA found "a lack of evidence to make a conclusion on the effectiveness of BPC-157" for ulcerative colitis.³
• Safety data. The human studies FDA identified were small and short, gave limited safety information, and mostly tested exploratory regimens. FDA also raised the possibility of immune reactions linked to impurities and aggregates.³

FDA also noted that approved medicines already exist for ulcerative colitis.³ These findings match what our BPC-157 research profile shows: most of the evidence comes from animal and laboratory studies. See human versus preclinical research for why that matters.

Some of these peptides had already left FDA's "safety risk" list

Several of these peptides had previously been in FDA's Category 2: substances under evaluation that FDA said may present significant safety risks in compounding. FDA's current page (content dated 22 April 2026) now lists BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, emideltide, GHK-Cu, LL-37, dihexa, Melanotan II and others as "nominated but withdrawn by nominators".¹⁰

Leaving Category 2 because a nomination was withdrawn is not the same as being cleared as safe. FDA chose to bring the July substances to the committee even though their nominations had been withdrawn.² GHRP-2, GHRP-6, ipamorelin and kisspeptin-10 still appear in Category 2.¹⁰

What happens next

1. FDA decides. The committee is advisory. FDA has said it will not make a final determination until the advisory process and its reviews are complete, and that the outcome "may be affected by issues not discussed" at the meeting.²
2. Rulemaking, if FDA agrees. Adding a substance to the 503A Bulks List requires a proposed rule in the Federal Register, a public comment period and a final rule. That usually takes many months. FDA could also decline.⁵
3. More peptides are in line. According to RAPS, FDA has said the committee will meet again before the end of February 2027 to review five more: LL-37, GHK-Cu, dihexa, Melanotan II and PEG-MGF.¹¹

Until a final rule is published, these peptides still do not meet the conditions of section 503A. Claims that BPC-157 or TB-500 are now "FDA-approved", "legal to compound" or "cleared by FDA" are incorrect.

Update, 12 October 2026: The Washington Post reported on 7 October that the administration is preparing a temporary measure that would allow some of these peptides to be sold before rulemaking is complete. The plan has not been announced, and its scope is unknown. Read what we know about the reported stopgap plan.

For athletes: peptides and the 2027 Prohibited List

WADA's Executive Committee approved the 2027 Prohibited List in September 2026, and it takes effect on 1 January 2027. According to the U.S. Anti-Doping Agency, "peptides" in general are now named as prohibited substances in S0, WADA's class for substances not approved for human therapeutic use. S0 substances are prohibited at all times, in and out of competition. USADA also advises that "even if a peptide is not specifically named on the List, utmost caution should be taken."⁸

This is mainly a clarification. Peptides such as BPC-157 were already caught by S0, and many growth-hormone-releasing peptides fall under S2. Semaglutide and tirzepatide remain permitted in 2027 but stay in WADA's Monitoring Program. A US compounding decision would not change any of this, because anti-doping rules are separate from FDA rules. See our guides to WADA peptide rules and peptides and athletes.

"Research use only" is not a loophole

On 24 August 2026, FDA's Center for Drug Evaluation and Research sent a warning letter to an online peptide seller. The letter concerned products including retatrutide (sold as "GLP-3R"), semaglutide, SS-31, PT-141 and tesamorelin, as well as bacteriostatic water. FDA concluded these were unapproved new drugs. The letter states that "evidence obtained from your website establishes that your products are intended to be drugs for human use", despite the "research use only" and "not for human consumption" labels.⁹

Several of those names, including tesamorelin, bremelanotide (PT-141) and elamipretide (SS-31), match ingredients in FDA-approved medicines. Retatrutide is still investigational. Sharing a name with an approved drug does not make an online vial an approved product. Read what "research use only" means and approved versus unapproved peptides.

What this means for you

• A committee vote is not an approval. No peptide in this review became FDA-approved, and none was added to the compounding list.
• The evidence has not changed. The vote does not create new human trial data. FDA's reviewers found the evidence insufficient for the specific uses they examined.
• Be wary of marketing that cites the vote. Clinics or sellers that present the vote as approval or proof of benefit are misrepresenting it. Our Check a Peptide Claim tool shows the evidence level and approval status for each peptide.
• Talk to a licensed clinician about any treatment decision, and use approved medicines with established evidence where they exist.

Frequently asked questions

Is BPC-157 FDA-approved now?

No. The July 2026 vote was an advisory recommendation about compounding. BPC-157 is not an ingredient of any FDA-approved medicine.¹³

Can pharmacies compound BPC-157 or TB-500 now?

Not under section 503A. They would first need to be added to the 503A Bulks List through a final rule, and as of 11 October 2026 FDA had not proposed one.²⁵

Did FDA staff support adding these peptides?

No. FDA's briefing documents proposed that none of the seven be added.²³

Are these peptides banned in sport?

Yes. From 1 January 2027, WADA's list names peptides in general under S0, and they are prohibited at all times. Many were already prohibited under earlier lists.⁸

Where can I follow what happens next?

Watch FDA's Pharmacy Compounding Advisory Committee page and the Federal Register. Our research updates and clinical trial tracker are refreshed as official information changes.